Treatment-emergent AEs by cohort, all grades, in ≥5% of patients
| . | Cohort 1 . | Cohort 2 . | Cohort 3 . | Cohort 3A . | Cohort 4 . | Cohort 5 . | Cohort 5A . | Total . |
|---|---|---|---|---|---|---|---|---|
| . | RO 0.30 mg/kg + venetoclax 400 mg, n (%) . | RO 0.45 mg/kg + venetoclax 400 mg, n (%) . | RO 0.45 mg/kg + venetoclax 600 mg, n (%) . | RO 0.45 mg/kg + venetoclax 600 mg + rituximab 375 mg/m2, n (%) . | RO 0.45 mg/kg + venetoclax 800 mg, n (%) . | RO 0.65 mg/kg + venetoclax 600 mg, n (%) . | RO 0.65 mg/kg + venetoclax 600 mg + rituximab 375 mg/m2, n (%) . | . |
| Patients, n | 3 | 6 | 9 | 7 | 4 | 4 | 6 | 39 |
| Injection site reaction | 2 (66.7) | 6 (100) | 6 (66.7) | 3 (42.9) | 2 (50.0) | 2 (50.0) | 3 (50.0) | 24 (61.5) |
| Diarrhea | 0 | 4 (66.7) | 5 (55.6) | 3 (42.9) | 3 (75.0) | 4 (100) | 4 (66.7) | 23 (59.0) |
| Nausea | 1 (33.3) | 4 (66.7) | 5 (55.6) | 3 (42.9) | 2 (50.0) | 2 (50.0) | 1 (16.7) | 18 (46.2) |
| Anemia | 0 | 4 (66.7) | 4 (44.4) | 1 (14.3) | 2 (50.0) | 3 (75.0) | 4 (66.7) | 18 (46.2) |
| Thrombocytopenia | 0 | 2 (33.3) | 4 (44.4) | 2 (28.6) | 0 | 3 (75.0) | 2 (33.3) | 13 (33.3) |
| Neutropenia | 1 (33.3) | 1 (16.7) | 5 (55.6) | 2 (28.6) | 0 | 2 (50.0) | 1 (16.7) | 12 (30.8) |
| Fatigue | 0 | 2 (33.3) | 2 (22.2) | 1 (14.3) | 2 (50.0) | 2 (50.0) | 2 (33.3) | 11 (28.2) |
| Hypomagnesemia | 0 | 2 (33.3) | 2 (22.2) | 0 | 2 (50.0) | 2 (50.0) | 2 (33.3) | 10 (25.6) |
| Decreased appetite | 1 (33.3) | 1 (16.7) | 1 (11.1) | 0 | 2 (50.0) | 1 (25.0) | 2 (33.3) | 8 (20.5) |
| Hypokalemia | 0 | 0 | 1 (11.1) | 1 (14.3) | 1 (25.0) | 1 (25.0) | 3 (50.0) | 7 (17.9) |
| Vomiting | 0 | 3 (50.0) | 2 (22.2) | 0 | 1 (25.0) | 1 (25.0) | 0 | 7 (17.9) |
| Peripheral edema | 0 | 1 (16.7) | 2 (22.2) | 2 (28.6) | 0 | 0 | 1 (16.7) | 6 (15.4) |
| Pyrexia | 0 | 1 (16.7) | 2 (22.2) | 1 (14.3) | 2 (50.0) | 0 | 0 | 6 (15.4) |
| Herpes zoster | 0 | 0 | 2 (22.2) | 0 | 2 (50.0) | 1 (25.0) | 1 (16.7) | 6 (15.4) |
| . | Cohort 1 . | Cohort 2 . | Cohort 3 . | Cohort 3A . | Cohort 4 . | Cohort 5 . | Cohort 5A . | Total . |
|---|---|---|---|---|---|---|---|---|
| . | RO 0.30 mg/kg + venetoclax 400 mg, n (%) . | RO 0.45 mg/kg + venetoclax 400 mg, n (%) . | RO 0.45 mg/kg + venetoclax 600 mg, n (%) . | RO 0.45 mg/kg + venetoclax 600 mg + rituximab 375 mg/m2, n (%) . | RO 0.45 mg/kg + venetoclax 800 mg, n (%) . | RO 0.65 mg/kg + venetoclax 600 mg, n (%) . | RO 0.65 mg/kg + venetoclax 600 mg + rituximab 375 mg/m2, n (%) . | . |
| Patients, n | 3 | 6 | 9 | 7 | 4 | 4 | 6 | 39 |
| Injection site reaction | 2 (66.7) | 6 (100) | 6 (66.7) | 3 (42.9) | 2 (50.0) | 2 (50.0) | 3 (50.0) | 24 (61.5) |
| Diarrhea | 0 | 4 (66.7) | 5 (55.6) | 3 (42.9) | 3 (75.0) | 4 (100) | 4 (66.7) | 23 (59.0) |
| Nausea | 1 (33.3) | 4 (66.7) | 5 (55.6) | 3 (42.9) | 2 (50.0) | 2 (50.0) | 1 (16.7) | 18 (46.2) |
| Anemia | 0 | 4 (66.7) | 4 (44.4) | 1 (14.3) | 2 (50.0) | 3 (75.0) | 4 (66.7) | 18 (46.2) |
| Thrombocytopenia | 0 | 2 (33.3) | 4 (44.4) | 2 (28.6) | 0 | 3 (75.0) | 2 (33.3) | 13 (33.3) |
| Neutropenia | 1 (33.3) | 1 (16.7) | 5 (55.6) | 2 (28.6) | 0 | 2 (50.0) | 1 (16.7) | 12 (30.8) |
| Fatigue | 0 | 2 (33.3) | 2 (22.2) | 1 (14.3) | 2 (50.0) | 2 (50.0) | 2 (33.3) | 11 (28.2) |
| Hypomagnesemia | 0 | 2 (33.3) | 2 (22.2) | 0 | 2 (50.0) | 2 (50.0) | 2 (33.3) | 10 (25.6) |
| Decreased appetite | 1 (33.3) | 1 (16.7) | 1 (11.1) | 0 | 2 (50.0) | 1 (25.0) | 2 (33.3) | 8 (20.5) |
| Hypokalemia | 0 | 0 | 1 (11.1) | 1 (14.3) | 1 (25.0) | 1 (25.0) | 3 (50.0) | 7 (17.9) |
| Vomiting | 0 | 3 (50.0) | 2 (22.2) | 0 | 1 (25.0) | 1 (25.0) | 0 | 7 (17.9) |
| Peripheral edema | 0 | 1 (16.7) | 2 (22.2) | 2 (28.6) | 0 | 0 | 1 (16.7) | 6 (15.4) |
| Pyrexia | 0 | 1 (16.7) | 2 (22.2) | 1 (14.3) | 2 (50.0) | 0 | 0 | 6 (15.4) |
| Herpes zoster | 0 | 0 | 2 (22.2) | 0 | 2 (50.0) | 1 (25.0) | 1 (16.7) | 6 (15.4) |